C07K 14/70535
Fc-receptors
Official title: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
C07K14/70535 (Fc-receptors) appears on 407 US grants and 705 published applications in this corpus.
Search patents in C07K- Granted patents
- 407
- Published applications
- 705
- Assignees
- 349
- Inventors
- 1,255
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 4 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 7 | 0 |
| 1998 | 9 | 0 |
| 1999 | 12 | 0 |
| 2000 | 11 | 0 |
| 2001 | 10 | 1 |
| 2002 | 8 | 10 |
| 2003 | 10 | 18 |
| 2004 | 3 | 17 |
| 2005 | 4 | 11 |
| 2006 | 15 | 16 |
| 2007 | 6 | 7 |
| 2008 | 8 | 12 |
| 2009 | 4 | 8 |
| 2010 | 6 | 11 |
| 2011 | 6 | 14 |
| 2012 | 11 | 9 |
| 2013 | 4 | 12 |
| 2014 | 11 | 12 |
| 2015 | 11 | 16 |
| 2016 | 8 | 18 |
| 2017 | 8 | 36 |
| 2018 | 15 | 36 |
| 2019 | 17 | 50 |
| 2020 | 27 | 52 |
| 2021 | 20 | 51 |
| 2022 | 35 | 61 |
| 2023 | 29 | 52 |
| 2024 | 28 | 77 |
| 2025 | 33 | 62 |
| 2026 | 15 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Non-human animals having humanized Fc-gamma receptors29 Sep 2026US 12,745,761 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for NK-92 cells expressing native CD1614 Jul 2026US 12,681,020 B2ImmunityBio, Inc.
- Mice expressing humanized Fc α receptors7 Jul 2026US 12,672,644 B2Regeneron Pharmaceuticals, Inc.
- CD155 variant immunomodulatory proteins and uses thereof12 May 2026US 12,624,087 B2Alpine Immune Sciences, Inc.
- Spacio-temporal determination of polypeptide structure21 Apr 2026US 12,609,183 B2Peptone, LTD.
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Multi-receptor natural killer cells17 Sep 2026US 2026/0275288 A1Board of Regents, The University of Texas System
- Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof3 Sep 2026US 2026/0256839 A1Century Therapeutics, Inc.
- Engineered natural killer cells with enhanced antitumor memory responses3 Sep 2026US 2026/0258360 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Recombinant production of immunoglobulin-like domains in prokaryotic cells477US 6,165,745 ABoard of Regents, The University of Texas System · 2000
- Chimeric chains for receptor-associated signal transduction pathways381US 5,359,046 ACell Genesys, Inc. · 1994
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Transgenic transchromosomal rodents for making human antibodies195US 7,041,870 B2Kirin Brewery Co., Ltd. · 2006